AmerisourceBergen Names Keri Mattox as Vice President, Corporate and Investor Relations

December 19, 2016

VALLEY FORGE, Pa.--(BUSINESS WIRE)--Dec. 19, 2016--AmerisourceBergen Corporation (NYSE: ABC) today announced that Keri Mattox will join the Company as Vice President, Corporate & Investor Relations, effective January 3, 2017. In this role, Ms. Mattox will assume responsibility for the Company’s relationships with the analyst and investor community, reporting directly to Tim G. Guttman, Executive Vice President and Chief Financial Officer.

Ms. Mattox succeeds Barbara A. Brungess, currently Vice President, Corporate & Investor Relations, who has announced that she is leaving the Company, effective December 31, 2016, to pursue other opportunities.

“I am delighted to have Keri lead our investor relations efforts going forward. In addition to the investor relations and healthcare industry experience she brings to AmerisourceBergen, Keri has established a great reputation and many strong relationships across the financial community,” said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. “We look forward to Keri’s contributions and support as AmerisourceBergen continues to pursue its long-term growth strategies in the global pharmaceutical supply chain.”

“I also want to thank Barbara for her leadership and dedication to AmerisourceBergen during the 16 years she has been with the Company,” Collis continued. “Barbara has made a significant impact on AmerisourceBergen during her tenure and helped us build and solidify relationships with the investment community. Her integrity, sound judgment and industry expertise have served AmerisourceBergen and our shareholders extremely well. It has been a pleasure working with Barbara, and we wish her all the best.”

Ms. Mattox brings over 15 years of investor relations and corporate communications experience spanning both corporate roles and public relations firms. She has significant experience within the specialty, generics and biotech pharmaceutical sectors. Most recently, Ms. Mattox served as Senior Vice President, Investor Relations & Corporate Public Affairs with Endo International, a role she assumed in 2015 following Endo’s acquisition of Auxilium Pharmaceuticals, where she led the investor relations function. At Endo, she was responsible for investor relations, corporate communications and government affairs. Ms. Mattox started her career in journalism with positions at the Washington Post and Hearst Newspapers before transitioning into public relations and then the pharmaceutical industry.

Ms. Mattox graduated magna cum laude with a bachelor’s degree in Political Science from Boston University and has her master’s degree in Journalism from the University of Maryland.

As of January 3, 2017, Ms. Mattox can be reached at AmerisourceBergen at 610-576-7801 and kmattox@amerisourcebergen.com.

In the interim period, Investor Relations questions can be directed to Bennett Murphy, Manager, Corporate & Investor Relations at 610-727-3693 and bmurphy@amerisourcebergen.com.

About AmerisourceBergen

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel in human and animal health. With over $145 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 19,000 people. AmerisourceBergen is ranked #12 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

AmerisourceBergen’s Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,” “will,” “project,” “intend,” “plan,” “continue,” “sustain,” “synergy,” “on track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,” “assume,” variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and change in circumstances. These statements are not guarantees of future performance and are based on assumptions that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: competition; industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in pharmaceutical market growth rates; unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; substantial defaults in payment, material reduction in or loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier mix; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms; the disruption of AmerisourceBergen’s cash flow and ability to return value to its stockholders in accordance with its past practices; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and AmerisourceBergen, including with respect to the pharmaceutical distribution agreement and/or the global sourcing arrangement; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; federal and state prosecution of alleged violations of related laws and regulations, and any related litigation, including shareholder derivative lawsuits or other disputes relating to our distribution of controlled substances; increased federal scrutiny and qui tam litigation for alleged violations of fraud and abuse laws and regulations and/or any other laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services and any related litigation; material adverse resolution of pending legal proceedings; declining reimbursement rates for pharmaceuticals; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, including the integration of PharMEDium, or the inability to capture all of the anticipated synergies related thereto; regulatory action in connection with the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business;
declining economic conditions in the United States and abroad; financial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; interest rate and foreign currency exchange rate fluctuations; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic sanctions and import laws and regulations; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; changes in tax laws or legislative initiatives that could adversely affect AmerisourceBergen's tax positions and/or AmerisourceBergen's tax liabilities or adverse resolution of challenges to AmerisourceBergen's tax positions; natural disasters or other unexpected events that affect AmerisourceBergen's operations; the impairment of goodwill or other intangible assets, resulting in a charge to earnings; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting AmerisourceBergen's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.


Source: AmerisourceBergen Corporation

AmerisourceBergen Corporation
Tim Guttman, 610-727-7000